WO2013058527A3 - Formulation combinée d'un antagoniste de leucotriène et de l'épinastine - Google Patents
Formulation combinée d'un antagoniste de leucotriène et de l'épinastine Download PDFInfo
- Publication number
- WO2013058527A3 WO2013058527A3 PCT/KR2012/008458 KR2012008458W WO2013058527A3 WO 2013058527 A3 WO2013058527 A3 WO 2013058527A3 KR 2012008458 W KR2012008458 W KR 2012008458W WO 2013058527 A3 WO2013058527 A3 WO 2013058527A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- epinastine
- leukotriene antagonist
- combined formulation
- active ingredients
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201280051128.XA CN103889424A (zh) | 2011-10-18 | 2012-10-17 | 白三烯拮抗剂和依匹斯汀的复合制剂 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110106382 | 2011-10-18 | ||
KR10-2011-0106382 | 2011-10-18 | ||
KR1020120069220A KR101278572B1 (ko) | 2011-10-18 | 2012-06-27 | 류코트리엔 길항제와 에피나스틴의 복합제제 |
KR10-2012-0069220 | 2012-06-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013058527A2 WO2013058527A2 (fr) | 2013-04-25 |
WO2013058527A3 true WO2013058527A3 (fr) | 2013-06-20 |
Family
ID=48141524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/008458 WO2013058527A2 (fr) | 2011-10-18 | 2012-10-17 | Formulation combinée d'un antagoniste de leucotriène et de l'épinastine |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013058527A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101230178B1 (ko) | 2010-06-10 | 2013-02-06 | 주식회사 네비팜 | 골다공증 예방 또는 치료용 조성물 및 이의 제조방법 |
CN103251563A (zh) * | 2013-05-22 | 2013-08-21 | 北京科源创欣科技有限公司 | 依匹斯汀或其盐酸盐的稳定的颗粒状药物组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100737710B1 (ko) * | 1997-12-23 | 2007-07-11 | 쉐링 코포레이션 | 하나 이상의 류코트리엔 길항제와 데스카보에톡실로라티딘를 포함하는 호흡기 질환 및 피부 질환 치료용 조성물 |
KR20080016621A (ko) * | 2005-06-09 | 2008-02-21 | 바이올리폭스 에이비 | 염증성 질병 치료용 조성물 및 방법 |
KR20090103810A (ko) * | 2008-03-28 | 2009-10-01 | 코와 가부시키가이샤 | 정제 |
US20110189274A1 (en) * | 2008-10-06 | 2011-08-04 | Swati Mukherjee | Stable Pharmaceutical Compositions Of Montelukast Or Its Salts Or Solvates Or Hydrates |
-
2012
- 2012-10-17 WO PCT/KR2012/008458 patent/WO2013058527A2/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100737710B1 (ko) * | 1997-12-23 | 2007-07-11 | 쉐링 코포레이션 | 하나 이상의 류코트리엔 길항제와 데스카보에톡실로라티딘를 포함하는 호흡기 질환 및 피부 질환 치료용 조성물 |
KR20080016621A (ko) * | 2005-06-09 | 2008-02-21 | 바이올리폭스 에이비 | 염증성 질병 치료용 조성물 및 방법 |
KR20090103810A (ko) * | 2008-03-28 | 2009-10-01 | 코와 가부시키가이샤 | 정제 |
US20110189274A1 (en) * | 2008-10-06 | 2011-08-04 | Swati Mukherjee | Stable Pharmaceutical Compositions Of Montelukast Or Its Salts Or Solvates Or Hydrates |
Non-Patent Citations (1)
Title |
---|
ALISE REICIN ET AL.: "Montelukast, a Leukotriene Receptor Antagonist, in Combination With Loratadine, a Histamine Receptor Antagonist, in the Treatment of Chronic Asthma", ARCHIVES INTERNAL MEDICINE, vol. 160, 2000, pages 2481 - 2488 * |
Also Published As
Publication number | Publication date |
---|---|
WO2013058527A2 (fr) | 2013-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012021715A3 (fr) | Formulations stables de linaclotide | |
IL229260A0 (en) | Preparations, methods and systems for respiratory administration of two or more active agents | |
WO2012016889A3 (fr) | Formulation de poudre sèche comprenant un inhibiteur de phosphodiestérase | |
WO2011086531A3 (fr) | Nouveaux agents antipaludiques | |
PH12014501967A1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
WO2013004995A8 (fr) | Composés pyrimidinones et leur utilisation | |
EP2941263A4 (fr) | Extrait purifié isolé à partir de pseudolysimachion rotundum var subintegrum contenant une grande quantité de principe actif, sa préparation et composition le comprenant comme principe actif pour prévenir une inflammation, une allergie et l'asthme | |
WO2013112959A8 (fr) | Composés antifibrotiques et leurs utilisations | |
WO2013055689A8 (fr) | R(+)-n-méthyl-propargyl-aminoindane | |
WO2012101653A3 (fr) | Compositions pharmaceutiques de mémantine à libération modifiée | |
EP2796450A4 (fr) | Dérivés 6-aminopyridine-3-ol ou leurs sels pharmaceutiquement acceptables, et composition pharmaceutique contenant ces dérivés ou ces sels comme principes actifs pour la prévention ou le traitement des maladies provoquées par l'angiogenèse | |
ZA201500362B (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
WO2012037562A3 (fr) | Compositions pharmaceutiques et nutraceutiques d'acide abscisique | |
WO2013093931A3 (fr) | Nouveaux promédicaments de médicaments phénoliques | |
PH12014501545A1 (en) | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
WO2012001705A3 (fr) | Compositions pharmaceutiques de (r)-lansoprazole | |
IL227024A (en) | The 3 heteroarylamino propionic acid derivatives are converted into amino acids, a process for their preparation, their use in the preparation of medicinal preparations and as medical preparations containing them | |
MD4563C1 (ro) | Produs de comicronizare cu conţinut de acetat de ulipristal | |
EP2722042A4 (fr) | Dérivés indanone, leurs isomères optiques ou leurs sels pharmaceutiquement acceptables, leur procédé de préparation, et des compositions pharmaceutiques les contenant en tant que principe actif pour prévenir ou traiter des maladies virales | |
EP2799082A4 (fr) | Composition pharmaceutique permettant de prévenir ou de traiter des maladies inflammatoires ou l'asthme, contenant un extrait de lagerstroemia ovalifolia ou une fraction de celle-ci en tant que principe actif | |
WO2012155226A8 (fr) | Procédé pour la production de dérivés de pyrostegia venusta, dérivés de pyrostegia venusta, compositions pharmaceutiques et leurs utilisations | |
WO2011139249A3 (fr) | Composition pharmaceutique renfermant du cefdinir | |
WO2013058527A3 (fr) | Formulation combinée d'un antagoniste de leucotriène et de l'épinastine | |
EP2875823A4 (fr) | Composition pharmaceutique destinée à la prévention et au traitement de bronchopneumopathies chroniques obstructives, contenant un extrait d'henosis stapf de la var. munro de phyllostachys nigra en tant que principe actif | |
WO2013188279A8 (fr) | Composition pharmaceutique ophtalmique topique contenant du cediranib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12841792 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2014536980 Country of ref document: JP Kind code of ref document: A |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22/08/2014) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12841792 Country of ref document: EP Kind code of ref document: A2 |